pharmachologic effect

Trimetazidine has an antihypoxic effect. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (enhancement of aerobic glycolysis and fat oxidation blockade).

Supports contractility of the myocardium, prevents the decrease in intracellular content of ATP and phosphocreatine. In conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the output of CKK from cells and the severity of ischemic myocardial damage.

When angina pectoris reduces the frequency of attacks and the need for nitroglycerin, after 2 weeks of treatment, exercise tolerance increases, improves the contractile function of the left ventricle in patients with ischemic dysfunction, decreases BP.

Reduces dizziness and tinnitus. In vascular pathology, the eye improves the functional activity of the retina.

Indications

- IHD: prevention of angina attacks (in complex therapy);

- cochlear-vestibular disorders of ischemic nature (dizziness, tinnitus, hearing impairment).